Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial

NCT05021731 is registered in ClinicalTrials.gov with Miguel Santín as lead sponsor.

NCT NCT05021731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial
Lead sponsor
Miguel Santín
Phase
Phase 4
Overall status
Unknown status
Start date
April 20, 2024
Completion date
April 30, 2025
Enrollment
225 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

kidney failure, latent tuberculosis